Genosys AI Healthcare, JG Group Sign 5 Billion Won Strategic Investment, Partnership Deal
by Lee Dong GeonPosted : April 27, 2026, 17:07Updated : April 27, 2026, 17:07
Genosys AI Healthcare has signed a 5 billion won strategic investment and broad business partnership agreement with JG Group.
Genosys AI Healthcare Co. (CEO Lee Hee-won, Genosys) said it signed the deal on April 24 with investment firm JG Group Co. (Chairman Lee Jae-gu, JG Group).
Under the agreement, the companies will jointly pursue an AI healthcare platform based on a Human Digital Twin (HDT) and a business to produce and distribute genome-based personalized health supplements. The total investment is 5 billion won.
Founded in 2022, Genosys is an AI healthcare company developing hyper-personalized health management services that integrate and analyze individual genomic information, multi-omics data and lifelog data. It aims to build a platform that links HDT-based disease risk prediction and health analysis to personalized supplement recommendations.
[Photo=Genosys AI Healthcare]
JG Group has invested mainly in real assets, consumer goods, food distribution and international resource infrastructure. It operates 11 affiliates in and outside South Korea, including JG Trading, JG Financial, JG Nature, JG HOLDINGS USA and JG International PNG, and said its investment assets total about 90 billion won.
The companies said they plan to combine Genosys’ AI healthcare technology with JG Group’s global distribution and infrastructure capabilities. Genosys said it will accelerate HDT platform development and expand infrastructure with the investment, while JG Group will participate in expanding healthcare and supplement businesses using Genosys’ technology.
They identified three main areas of cooperation. First, they will jointly develop an HDT-based AI healthcare platform designed to analyze multi-omics data — including genomics, proteomics and metabolomics — to predict health status and disease risk and provide personalized health management solutions.
Second, they will work on production and distribution of genome-tailored health supplements. Genosys said it will expand its lineup based on genomic analysis results, and JG Group said it will support market entry using its domestic and overseas distribution networks. Genosys’ supplement brand GenoBioFit is expected to be included in future cooperation.
Third, they plan a medical consulting and clinic management support business, combining AI-based medical management solutions with operational support services to build a business-to-business model.
“Genosys AI Healthcare will change the paradigm of disease prediction, prevention and personalized treatment through Human Digital Twin technology,” Lee said, calling the partnership with JG Group “a decisive turning point” to implement that vision.
Lee Jae-gu, chairman of JG Group, said the group has added strategic value to promising growth companies based on real assets and a global network. He said Genosys’ AI healthcare technology and JG’s investment and distribution capabilities will work together to build a healthcare platform aimed at leading the Asia-Pacific market.
The companies said they plan to complete payment of the full 5 billion won investment by Aug. 31. Of that, 2.5 billion won will be used as Genosys development and operating funds for advancing the HDT platform and expanding clinical applications. The remaining 2.5 billion won will be used to establish a new business entity jointly funded 50-50 by the two companies.
Genosys said it plans to launch a beta version of the platform and expand its supplement line in the second half of 2026. It said it will then use JG Group’s distribution networks to target both consumer and business markets, and will also review entry into North America and Oceania through cooperation with JG HOLDINGS USA and JG International PNG.
